Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLSEEK-4: Golcadomide + Rituximab vs Investigator’s Choice in Relapsed/Refractory Follicular Lymphoma
jRCT2011260015Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of golcadomide in follicular lymphoma (FL) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival. Started Sep 2025; status: recruiting.
02
Drugs
golcadomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2011260015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260015.